$PYXS 8-K SEC Filings

Filed On	Filing
01 Oct 2026	8-K: Entry into a Material Definitive Agreement; Other Events Common Warrants to Purchase up to 49,310,352 Shares of Common Stock
09 Sep 2026	8-K: Regulation FD Disclosure; Other Events Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
08 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board
13 Aug 2026	8-K: Results of Operations and Financial Condition
02 Jul 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
15 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
14 May 2026	8-K: Results of Operations and Financial Condition
23 Mar 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
06 Feb 2026	8-K: Financial Statements and Exhibits
18 Dec 2025	8-K: Regulation FD Disclosure; Other Events
03 Nov 2025	8-K: Results of Operations and Financial Condition
14 Aug 2025	8-K: Results of Operations and Financial Condition
04 Aug 2025	8-K: Other Events
03 Jul 2025	8-K: Departure/Election of Directors or Officers; Compensation
18 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
15 May 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
24 Mar 2025	8-K: Regulation FD Disclosure
18 Mar 2025	8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
26 Feb 2025	8-K: Other Events
04 Feb 2025	8-K: Other Events

Comments